Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM6603 in advanced solid tumors
NCT07292038Phase 1Recruiting
- Sponsor
- Nucmito Pharmaceuticals Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NM6603 in colorectal cancer (CRC), triple-negative breast cancer (TNBC) and solid tumor, sponsored by Nucmito Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase II Dose at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
NM6603
03
Conditions
colorectal cancer (CRC)triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT07292038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292038.